Clinical analysis of drug treatment trends for coronary heart disease in China
Xu Li, Junyi Lou, Xiaoyu Li, Shuang Li, Junxian Gu, Die Zhang, Zining Luo, Junjie Cao, Jiebin Xie · 2026
Read Clinical analysis of drug treatment trends for coronary heart disease in China by Xu Li, Junyi Lou, Xiaoyu Li, Shuang Li, Junxian Gu, Die Zhang, Zining Luo, Junjie Cao, Jiebin Xie (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13286841.txt.
Description
Xu Li and co-authors compare China's coronary heart disease research output with its clinical drug trial activity, asking whether investment matches treatment priorities. The 2026 analysis screened thousands of publications and over a thousand registered drug trials, classifying drugs and traditional Chinese medicine ingredients with standard systems.
Publications grew steeply over two decades. Yet more than three quarters of trials merely proved that generic copies match originals, and chemical drugs dominated over traditional medicine entries. Genetic research clustered on inflammation markers while lipid targets, central to standard therapy, were neglected. High-prestige journals carried a minority of the work. The authors call the landscape policy-driven and urge rebalancing toward novel drugs and lipid genetics.
Catalog record
| CREATOR | Xu Li, Junyi Lou, Xiaoyu Li, Shuang Li, Junxian Gu, Die Zhang, Zining Luo, Junjie Cao, Jiebin Xie |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 54 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |